Tab. III.
GPs' involvement in monitoring clinical indicators and side effects of antiviral treatment.
| GPs involvement in monitoring ALT | ||||||
| ACCORDING TO GPs | UK (n = 10) | DE (n = 4) | NL (n = 9) | HU (n = 1) | IT (n = 14) | ES (n = 2) |
| Very common | 20% | 75% | 0% | 100% | 64% | 50% |
| Variable or not routinely | 40% | 0% | 22% | 0% | 21% | 50% |
| Rarely or never | 20% | 0% | 56% | 0% | 14% | 0% |
| Unsure | 20% | 25% | 22% | 0% | 0% | 0% |
| ACCORDING TO SPECIALISTS | UK (n = 10) | DE (n = 9) | NL (n = 22) | HU (n = 10) | IT (n = 9) | ES (n = 4) |
| Very common | 0% | 56% | 0% | 10% | 33% | 0% |
| Variable or not routinely | 10% | 11% | 23% | 10% | 67% | 100% |
| Rarely or never | 90% | 11% | 77% | 60% | 0% | 0% |
| Unsure | 0% | 22% | 0% | 20% | 0% | 0% |
| COMBINED RESULTS | UK (n = 20) | DE (n = 13) | NL (n = 31) | HU (n = 11) | IT (n = 23) | ES (n = 6) |
| Very common | 10% | 62% | 0% | 18% | 52% | 17% |
| Variable or not routinely | 25% | 8% | 23% | 9% | 39% | 83% |
| Rarely or never | 55% | 8% | 71% | 55% | 9% | 0% |
| Unsure | 10% | 23% | 6% | 18% | 0% | 0% |
| GPs involvement in monitoring viral load | ||||||
| ACCORDING TO GPs | UK (n = 10) | DE (n = 4) | NL (n = 9) | HU (n = 1) | IT (n = 14) | ES (n = 2) |
| Very common | 0% | 50% | 0% | 0% | 36% | 0% |
| Variable or not routinely | 30% | 25% | 11% | 0% | 43% | 50% |
| Rarely or never | 50% | 25% | 67% | 100% | 21% | 50% |
| Unsure | 20% | 0% | 22% | 0% | 0% | 0% |
| ACCORDING TO SPECIALISTS | UK (n = 10) | DE (n = 9) | NL (n = 22) | HU (n = 10) | IT (n = 9) | ES (n = 4) |
| Very common | 0% | 33% | 0% | 0% | 22% | 0% |
| Variable or not routinely | 0% | 22% | 0% | 10% | 11% | 25% |
| Rarely or never | 100% | 22% | 100% | 70% | 67% | 75% |
| Unsure | 0% | 22% | 0% | 20% | 0% | 0% |
| COMBINED RESULTS | UK (n = 20) | DE (n = 13) | NL (n = 31) | HU (n = 11) | IT (n = 23) | ES (n = 6) |
| Very common | 0% | 38% | 0% | 0% | 30% | 0% |
| Variable or not routinely | 15% | 23% | 3% | 9% | 30% | 33% |
| Rarely or never | 75% | 23% | 90% | 73% | 39% | 67% |
| Unsure | 10% | 15% | 6% | 18% | 0% | 0% |
| GPs involvement in monitoring side effects | ||||||
| ACCORDING TO GPs | UK (n = 10) | DE (n = 4) | NL (n = 9) | HU (n = 1) | IT (n = 14) | ES (n = 2) |
| Very common | 10% | 75% | 0% | 0% | 50% | 100% |
| Variable or not routinely | 50% | 0% | 22% | 100% | 36% | 0% |
| Rarely or never | 20% | 25% | 56% | 0% | 14% | 0% |
| Unsure | 20% | 0% | 22% | 0% | 0% | 0% |
| ACCORDING TO SPECIALISTS | UK (n = 10) | DE (n = 9) | NL (n = 22) | HU (n = 10) | IT (n = 9) | ES (n = 4) |
| Very common | 10% | 56% | 0% | 10% | 11% | 0% |
| Variable or not routinely | 40% | 11% | 46% | 20% | 78% | 50% |
| Rarely or never | 50% | 11% | 55% | 40% | 11% | 50% |
| Unsure | 0% | 22% | 0% | 30% | 0% | 0% |
| COMBINED RESPONSES | UK (n = 20) | DE (n = 13) | NL (n = 31) | HU (n = 11) | IT (n = 23) | ES (n = 6) |
| Very common | 10% | 62% | 0% | 9% | 35% | 33% |
| Variable or not routinely | 45% | 8% | 39% | 27% | 52% | 33% |
| Rarely or never | 35% | 15% | 55% | 36% | 13% | 33% |
| Unsure | 10% | 15% | 7% | 27% | 0% | 0% |